Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.44 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743554 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4ERAB9AELANEMEN1 | |
| SCHEMBL1665765 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4ERAB9AAKR1C3AKR1C2 | |
| SCHEMBL26417680 | 0.81 | ELANE (0.46) | ALDH1A1KDM4ERAB9AELANEMEN1 | |
| SCHEMBL1743408 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4ERAB9ATRPM4GRIK1 | |
| SCHEMBL7780345 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4EELANEAKR1C3AKR1C2 | |
| SCHEMBL12798622 | 0.77 | GRIK1 (0.51) | ALDH1A1KDM4ERAB9ATRPM4GRIK1 | |
| SCHEMBL21464391 | 0.77 | KDM4E (0.61) | ALDH1A1KDM4EAKR1C3AKR1C2GRIK1 | |
| SCHEMBL13178173 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4ERAB9ATRPM4GRIK1 | |
| SCHEMBL14517594 | 0.75 | ALDH1A1 (0.48) | ALDH1A1KDM4ERAB9ATRPM4GRIK1 | |
| SCHEMBL1663739 | 0.72 | MAPT (0.56) | ALDH1A1RAB9AGRIK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387440-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| EP-2387440-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | CHEN WEICHUN (US) | 2013-03-07 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2387440-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254530-A1 | FAULT PROTECTED CURRENT SOURCE FOR LIGHTING ELEMENT TESTING | VEKTREX ELECTRONIC SYSTEMS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| WO-2010084050-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084050-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | KCNA4, KCNA3, KCNB1 | ALDH1A1 1332/4885KDM4E 1546/4885RAB9A 1737/4885 |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, KCNJ2, TRPV3 | ALDH1A1 876/4885KDM4E 1597/4885RAB9A 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.